aromasil has been researched along with Neoplasm Metastasis in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.67) | 18.2507 |
| 2000's | 19 (31.67) | 29.6817 |
| 2010's | 32 (53.33) | 24.3611 |
| 2020's | 8 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Acikgoz, O; Akin, S; Avci, N; Basaran, G; Beypinar, I; Bilgetekin, I; Bilici, A; Cinkir, HY; Değirmenci, M; Demir, A; Dogan, M; Erdem, D; Kaplan, MA; Menekse, S; Olmez, OF; Paydas, S; Sakalar, T; Sakin, A; Sezgin Goksu, S; Tanriverdi, O; Temiz, S; Tural, D; Turan, M; Turhal, S; Turker, S; Uslu, R; Uysal, M; Yildiz, F | 1 |
| Abramson, VG; Del Valle, L; Ismail-Khan, R; Lush, RM; Majumder, S; Mayer, IA; Means-Powell, JA; Miele, L; Sanders, MS; Sorrentino, C; Tonetti, D | 1 |
| Ahn, HK; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kang, SY; Kim, GM; Kim, HJ; Kim, JH; Kim, JY; Kim, SB; Kim, TY; Koh, SJ; Lee, JI; Lee, KE; Lee, KH; Lee, MH; Park, IH; Park, YH; Sohn, J | 1 |
| Boven, E; Dercksen, WM; Jager, A; Jansen, MPHM; Konings, IRHM; Kruger, DT; Martens, JWM; Oulad Hadj, J; Sleijfer, S | 1 |
| Bianchi, GV; Capri, G; Corti, F; de Braud, F; Ligorio, F; Manglaviti, S; Nichetti, F; Rea, CG; Vernieri, C; Zattarin, E | 1 |
| Adachi, M; Amemiya, T; Hata, H; Hayashi, N; Kashiwabara, K; Kikawa, Y; Kondo, N; Mitsunaga, S; Mukai, H; Naito, M; Nakagami, K; Nakatsukasa, K; Niikura, N; Ota, Y; Shibuya, Y; Taniike, N; Umeda, M; Watanabe, KI; Yamanaka, T; Yamashita, T | 1 |
| Adamson, D; Bergh, J; Bogenrieder, T; Cortés, J; Crown, J; Espadero, RM; Gonçalves, A; Huang, DC; Im, SA; Jerusalem, G; Lee, KS; Lu, YS; Martínez, N; Morales, S; Neven, P; Pérez-Fidalgo, JA; Prat, A; Sablin, MP; Schlieker, L; Schmid, P | 1 |
| Apostolaki, S; Georgoulia, N; Georgoulias, V; Hatzidaki, D; Kallergi, G; Koinis, F; Kotsakis, A; Nikolaou, C; Politaki, E; Spiliotaki, M; Tsoukalas, N; Xenidis, N | 1 |
| Alba, E; Alvarez, E; Antón, A; Bermejo, B; Calvo, L; Carrasco, E; Casas, M; Ciruelos, E; Corsaro, M; Csöszi, T; de la Haba-Rodriguez, J; Gal-Yam, E; Garcia-Palomo, A; Gil-Gil, M; González-Santiago, S; Kahan, Z; Lang, I; López, IÁ; Margeli, M; Martín, M; Morales, S; Muñoz, M; Murillo, L; Ramos, M; Rodrigálvarez, G; Rodríguez, CA; Ruiz-Borrego, M; Servitja, S; Zielinski, C | 1 |
| Beck, JT; Chambers, MS; Dhillon, N; Glaspy, JA; Hwang, LC; Litton, JK; Mayer, IA; Meiller, TF; Nangia, C; Peguero, JA; Pluard, TJ; Rugo, HS; Sabo, JR; Seneviratne, L; Sweetman, RW | 1 |
| Ascione, G; Barone, CA; Bighin, C; Bordonaro, R; Cazzaniga, ME; Cognetti, F; Foglietta, J; Frassoldati, A; Generali, D; Goffredo, F; Ionta, MT; Latini, L; Mafodda, A; Mariani, G; Michelotti, A; Minisini, AM; Molino, A; Montemurro, F; Nolè, F; Nuzzo, F; Piacentini, F; Piovano, P; Portera, G; Riccardi, F; Roila, F; Romito, S; Sartori, D; Schirone, A; Simoncini, EL; Testore, F; Vici, P | 1 |
| Alvarez, I; Andersen, J; Bertelli, G; Bliss, JM; Coates, AS; Coleman, R; Coombes, RC; Del Mastro, L; Dodwell, D; Fallowfield, L; Holmberg, S; Jassem, J; Jones, S; Kilburn, L; Lønning, PE; Morden, JP; Nicholas, H; Ortmann, O; Paridaens, R; Snowdon, C; van de Velde, C | 1 |
| Airoldi, M; Arcangeli, V; Artale, S; Atzori, F; Ballerio, A; Bianchi, GV; Blasi, L; Campidoglio, S; Cazzaniga, ME; Ciccarese, M; Clivio, L; Cursano, MC; Fabi, A; Ferrari, L; Ferzi, A; Ficorella, C; Frassoldati, A; Fumagalli, A; Garrone, O; Gebbia, V; Generali, D; La Verde, N; Maur, M; Michelotti, A; Moretti, G; Musolino, A; Palumbo, R; Piezzo, M; Pistelli, M; Porpiglia, M; Sartori, D; Scavelli, C; Schirone, A; Torri, V; Turletti, A; Valerio, MR; Vici, P; Zambelli, A | 1 |
| Beliera, A; Carabantes, F; Ciruelos, E; Fernández, Y; Fonseca, R; García-Sáenz, JA; Gavilá, J; Martínez de Dueñas, E; Martínez-Jáñez, N; Murillo, L; Vidal, M | 1 |
| Kubo, H; Maeda, N; Nagano, H; Nagashima, Y; Sakamoto, K; Sato, Y; Suzuki, N; Takeda, S; Yamamoto, S | 1 |
| Bufill, JA; Cella, D; Chapman, JW; Goss, PE; LaFrancis, IE; Mattar, BI; Nagargoje, GG; Nikcevich, DA; Schultz, WC; Shepherd, LE; Sledge, GW; Vemuri, R; Wagner, LI; Whelan, TJ; Zhao, F | 1 |
| Decker, T; Distelrath, A; Fasching, PA; Hadji, P; Janni, W; Kreuzeder, J; Kurbacher, CM; Lüftner, D; Lux, MP; Marmé, F; Mundhenke, C; Muth, M; Quiering, C; Schneeweiss, A; Stoetzer, O; Taran, FA; Tesch, H | 1 |
| Chen, Z; Gong, C; Hu, S; Hu, X; Li, Y; Wang, B; Wang, L; Xie, Y; Yuan, P; Zhang, J; Zhang, Y; Zhao, Y | 1 |
| Cao, E; Ge, R; Gong, C; Guan, X; Hu, X; Li, W; Li, Y; Wang, B; Wang, L; Xie, Y; Zhang, J; Zhang, S; Zhang, Y; Zhao, Y | 1 |
| Benelli, M; Bergqvist, M; Biagioni, C; Biganzoli, L; Boccalini, G; Bonechi, M; Chia, S; De Luca, F; Di Leo, A; Galardi, F; Gradishar, WJ; Malorni, L; Mattsson, K; McCartney, A; Migliaccio, I; Pestrin, M; Piccart, M; Romagnoli, D; Schiavon, G | 1 |
| Cruickshank, S; Ismail-Khan, RR; Klein, PM; Lee, MJ; Lichinitser, M; Melichar, B; Miller, KD; Munster, PN; Trepel, JB; Yardley, DA | 1 |
| Arena, F; Bachelot, T; Baselga, J; Burris, HA; Campone, M; Deleu, I; El-Hashimyt, M; Gnant, M; Hart, L; Héniquez, A; Hortobagyi, GN; Melichar, B; Noguchi, S; Panneerselvam, A; Piccart, M; Pistilli, B; Pritchard, KI; Provencher, L; Rugo, HS; Sahmoud, T; Shtivelband, M; Taran, T | 1 |
| Bliss, JM; Braybrooke, JP; Brunt, AM; Cameron, D; Cheung, KL; Coombes, G; Dodwell, D; Dowsett, M; Ellis, P; Folkerd, E; Hayward, L; Howell, A; Im, YH; Johnston, SR; Jyothirmayi, R; Kilburn, LS; Robinson, A; Sergenson, N; Sin, HJ; Wardley, AM; Wheatley, D | 1 |
| Baselga, J; Bourgeois, H; Burris, HA; Campone, M; Csöszi, T; Dakhil, S; Gnant, M; Gonzalez Martin, A; Heng, D; Hortobagyi, GN; Ito, Y; Noguchi, S; Osborne, K; Panneerselvam, A; Piccart, M; Pritchard, KI; Puttawibul, P; Rugo, HS; Sahmoud, T; Srimuninnimit, V; Taran, T | 1 |
| Adunlin, G; Avancha, K; Diaby, V; Gluck, S; Lopes, G; Montero, AJ; Zeichner, SB | 1 |
| Abrial, C; Arbre, M; Chollet, P; Devaud, H; Dohou, J; Dubray-Longeras, P; Durando, X; Herviou, P; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Planchat, E; Pouget, M; Van Praagh, I | 1 |
| Cui, S; Lü, H; Niu, L; Yan, M; Zeng, H; Zhang, M | 1 |
| Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M | 1 |
| Bachelot, T; Béal-Ardisson, D; Becuwe, C; Blot, E; Bürki, F; Cropet, C; Dauba, J; Diéras, V; Follana, P; Gouttebel, M; Guardiola, E; Jouannaud, C; Lavau-Denes, S; Moullet, I; Orfeuvre, H; Petit, T; Pujade-Lauraine, E; Stefani, L; Trager-Maury, S; Trédan, O | 1 |
| Goto, Y; Kimura, M; Sakiyama, K; Yoshida, T | 1 |
| Arellano, C; Chatelut, E; Dalenc, F; Filleron, T; Iuliano, L; Marquet, P; Poirot, M; Roché, H; Samadi, M; Silvente-Poirot, S; Voisin, M; Zerbinati, C | 1 |
| Bianchetti, S; Camozzi, M; Ciruelos, EM; Conte, P; Gavila, JG; Generali, D; Jerusalem, G; Lang, I; Lorizzo, K; Mardiak, J; Mariani, G; Martin, M; Michelotti, A; Montemurro, F; Naume, B; Neven, P; Simoncini, E; Tjan-Heijnen, VC | 1 |
| Cortesi, E; D'Onofrio, L; Fabbri, MA; Gamucci, T; Giuliani, R; Iezzi, L; Magri, V; Mancini, ML; Marchetti, P; Mauri, M; Mentuccia, L; Moscetti, L; Natoli, C; Pizzuti, L; Ramponi, S; Roma, CL; Ruggeri, EM; Santini, D; Sini, V; Sperduti, I; Vaccaro, A; Vici, P | 1 |
| Allred, DC; Babiera, G; Barnes, M; Brink, A; Budd, GT; Carey, L; Creighton, CJ; Crouch, E; Dayao, Z; DeSchryver, K; Dowsett, M; Ellis, MJ; Esserman, L; Goncalves, R; Guenther, JM; Hoog, J; Hunt, K; Leitch, M; Luo, J; Ma, CX; Olson, JA; Ota, D; Pluard, T; Sanati, S; Silverman, P; Suman, VJ; Tao, Y; Unzeitig, G; Watson, M; Whitworth, P; Winer, E | 1 |
| Baselga, J; Bhatt, T; Chandarlapaty, S; Chen, D; He, W; Hortobagyi, GN; Moynahan, ME; Patel, P; Ringeisen, F; Samoila, A; Sung, P; You, D | 1 |
| Geisler, J; Lønning, PE | 1 |
| Doyen, J; Ferrero, JM; Fontana, X; Italiano, A; Largillier, R; Thyss, A | 1 |
| Banerjee, M; Cooksley, T; Younis, N | 1 |
| Doughty, JC | 1 |
| Cruz Jurado, J; Fernández Martínez, R; Galve Calvo, E; García Mata, J; García Palomo, A; Murillo Jaso, L; Peláez Fernández, I; Polo Marqués, E; Richart Aznar, P; Sampedro Gimeno, T | 1 |
| Kim, SH; Lee, H; Lee, KS; Nam, BH; Park, IH; Ro, J | 1 |
| Bajetta, E; Bombardieri, E; Buzzoni, R; Celio, L; Ferrari, L; Gattinoni, L; La Torre, I; Longarini, R; Martinetti, A; Seregni, E | 1 |
| Brodie, AH; Mouridsen, HT | 1 |
| Rose, C | 1 |
| Gershanovich, M; Mouridsen, H | 1 |
| Ingle, JN | 1 |
| Atalay, G; Beex, L; Biganzoli, L; Cameron, D; Cufer, T; Dirix, L; Lobelle, JP; Lohrisch, C; Mattiaci, MR; Nooij, M; Paridaens, R; Piccart, M | 1 |
| Asnis, AG; Duncan, B; Francis, D; Hortobagyi, GN; Rivera, E; Schaaf, LJ; Valero, V | 1 |
| Mouridsen, HT | 1 |
| Baelde, HJ; Bovée, JV; Cleton-Jansen, AM; Hogendoorn, PC; Karperien, M; van Beerendonk, HM | 1 |
| Abrial, C; Cabrespine, A; Chollet, P; Cure, H; Durando, X; Ferriere, JP; Kwiatkowski, F; Leheurteur, M; Mouret-Reynier, MA; Penault-Llorca, F | 1 |
| Blackwell, KL; Herold, CI | 1 |
| Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Shiiki, S; Sonoo, H; Tanaka, K; Yamamoto, Y | 1 |
| Di Salle, E; Engan, T; Johannessen, DC; Kvinnsland, S; Lonning, PE; Ornati, G; Paolini, J; Piscitelli, G; Zurlo, MG | 1 |
| Aaronson, NK; Arkhipov, A; Bajetta, E; Celio, L; di Salle, E; Eisenberg, PD; Fowst, C; Lønning, PE; Massimini, G; Mickiewicz, E; Mita, M; Murray, R; Pitt, P; Polli, A; Tubiana-Hulin, M | 1 |
| Anker, G; Bonneterre, J; di Salle, E; Dirix, LY; Kvinnsland, S; Lobelle, JP; Mariani, O; Massimini, G; Polli, A; Prove, AM; Wilking, N | 1 |
| Cattel, F; Messori, A; Trippoli, S; Vaiani, M | 1 |
| Arkhipov, A; Bajetta, E; Cervek, J; di Salle, E; Dirix, LY; Dugardyn, JL; Fein, LE; Fowst, C; Jones, SE; Kaufmann, M; Massimini, G; Mennel, RG; Miller, LL; Nasurdi, C; Piscitelli, G; Polli, A; Zilembo, N | 1 |
| Beex, L; Biganzoli, L; Cufer, T; Dirix, L; Duchateau, L; Lobelle, JP; Lohrisch, C; Nooij, M; Paridaens, R; Piccart, M; Van Hoorebeeck, I | 1 |
| Crucitta, E; De Lena, M; Fornier, MN; Locopo, N; Lorusso, V; Silvestris, N | 1 |
11 review(s) available for aromasil and Neoplasm Metastasis
| Article | Year |
|---|---|
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Everolimus; Female; Humans; Mechanistic Target of Rapamycin Complex 1; Multicenter Studies as Topic; Neoplasm Metastasis; Patient Safety; Phosphatidylinositol 3-Kinases; Prospective Studies; Proto-Oncogene Proteins c-akt; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2020 |
Experience with exemestane in the treatment of early and advanced breast cancer.
Topics: Androstadienes; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neoplasm Metastasis | 2008 |
When to start an aromatase inhibitor: now or later?
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2011 |
Management of patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease Management; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles | 2011 |
Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays | 2003 |
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
The role of aromatase inhibitors in the treatment of metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Triazoles | 2003 |
Aromatase inhibitors in advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2004 |
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Evidence-Based Medicine; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol; Neoplasm Metastasis; Nitriles; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Triazoles | 2000 |
Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (Review).
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Neoplasm Metastasis | 2002 |
25 trial(s) available for aromasil and Neoplasm Metastasis
| Article | Year |
|---|---|
A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC).
Topics: Aged; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorocarbons; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Receptor, Notch3; Receptors, Notch | 2022 |
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Drug Therapy, Combination; Female; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Middle Aged; Neoplasm Metastasis; Piperazines; Prognosis; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2019 |
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Everolimus; Female; Follow-Up Studies; Humans; Japan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oral Health; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Stomatitis; Survival Rate | 2021 |
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease Management; Everolimus; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2021 |
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
Topics: Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Disease Progression; Estrogen Receptor Antagonists; Europe; Female; Fulvestrant; Health Status; Humans; Israel; Neoplasm Metastasis; Patient Reported Outcome Measures; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quality of Life; Time Factors | 2021 |
Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
Topics: Administration, Topical; Aged; Androstadienes; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Drug Eruptions; Dyspnea; Everolimus; Female; Humans; Hyperglycemia; Middle Aged; Mouthwashes; Neoplasm Metastasis; Pneumonia; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Severity of Illness Index; Stomatitis | 2017 |
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Everolimus; Female; Humans; Italy; Middle Aged; Neoplasm Metastasis | 2017 |
Long-Term Follow-Up of the Intergroup Exemestane Study.
Topics: Aged; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Receptors, Estrogen; Survival Rate; Tamoxifen; Time Factors | 2017 |
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Safety; Survival Rate | 2018 |
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).
Topics: Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Fulvestrant; Humans; Neoplasm Metastasis; Prognosis; Thymidine Kinase | 2019 |
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromata
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postmenopause; Pyridines; Receptors, Estrogen | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2013 |
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; International Agencies; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Safety; Sirolimus; Survival Rate | 2013 |
A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Estrogen Receptor alpha; Female; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2 | 2016 |
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, e
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Everolimus; Female; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus | 2016 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Decision-Making; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Mitotic Index; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Transcriptome; Triazoles | 2017 |
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell-Free System; Class I Phosphatidylinositol 3-Kinases; DNA Mutational Analysis; DNA, Neoplasm; Everolimus; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Mutation; Neoplasm Metastasis; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2017 |
The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamo
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arteriosclerosis; Breast Neoplasms; Cholesterol; Enzyme Inhibitors; Female; Humans; Lipids; Middle Aged; Neoplasm Metastasis; Postmenopause; Risk Factors; Tamoxifen | 2004 |
Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrone; Female; History, 18th Century; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pilot Projects; Tamoxifen | 2004 |
Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
Topics: Aged; Alprostadil; Androgens; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Dinoprostone; Dose-Response Relationship, Drug; Drug Administration Schedule; Estradiol; Estrone; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Postmenopause | 1997 |
Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chi-Square Distribution; Female; Humans; Middle Aged; Neoplasm Metastasis; Palliative Care; Postmenopause; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2000 |
High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Tamoxifen; Treatment Failure | 2000 |
Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study.
Topics: Administration, Oral; Aged; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Humans; Megestrol Acetate; Middle Aged; Neoplasm Metastasis; Postmenopause; Survival Analysis; Treatment Outcome | 2000 |
Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control.
Topics: Administration, Oral; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Female; Humans; Neoplasm Metastasis; Tamoxifen; Treatment Outcome | 2000 |
24 other study(ies) available for aromasil and Neoplasm Metastasis
| Article | Year |
|---|---|
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Treatment Outcome; Turkey | 2022 |
High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Everolimus; Female; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation, Missense; Neoplasm Metastasis; Postmenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies | 2020 |
Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(-) breast cancer receiving salvage treatment with everolimus/exemestane.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Everolimus; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; Receptor, ErbB-2; Salvage Therapy; Treatment Outcome | 2021 |
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptor, ErbB-2 | 2017 |
[Efficacy and Safety of Everolimus plus Exemetane in Postmenopausal Endocrine-Responsive Metastatic Breast Cancer Patients].
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Endocrine System; Everolimus; Female; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause | 2017 |
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Medication Adherence; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Patient Reported Outcome Measures; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic | 2018 |
Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Breast Neoplasms; Capecitabine; Disease Progression; Everolimus; Female; Fulvestrant; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Receptor, ErbB-2; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2019 |
Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate | 2019 |
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Everolimus; Exanthema; Fatigue; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Placebos; Postmenopause; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Steroid; Sirolimus; Stomatitis; Treatment Outcome; Viscera | 2013 |
Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Everolimus; Female; Humans; Markov Chains; Neoplasm Metastasis; Sirolimus | 2014 |
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Estradiol; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Prognosis; Retrospective Studies; Survival Rate; Tamoxifen; Triazoles | 2015 |
[Efficacies of aromatase inhibitors in the treatment of hormone dependent metastatic breast cancer in postmenopausal women: a report of 148 cases].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Hormones; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Postmenopause; Triazoles | 2015 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles | 2016 |
[An Elderly Patient with Metastatic Breast Cancer Who Developed Severe Adverse Events such as Stomatitis and Interstitial Pneumonia after Everolimus plus Exemestane Treatment].
Topics: Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Lung Diseases, Interstitial; Neoplasm Metastasis; Stomatitis; Thoracic Wall | 2016 |
Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study.
Topics: Adult; Aged; Androstadienes; Aromatase; Aromatase Inhibitors; Biomarkers; Body Mass Index; Breast Neoplasms; Cholestanes; Cholesterol; Feasibility Studies; Female; Gas Chromatography-Mass Spectrometry; Hormones; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Oxidative Stress; Oxysterols; Pilot Projects; Prognosis; Prospective Studies; Reproducibility of Results; Signal Transduction; Tamoxifen; Triazoles | 2017 |
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Everolimus; Female; Humans; Italy; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Receptor, ErbB-2; Regression Analysis; Retrospective Studies; Treatment Outcome | 2016 |
Aromatase inhibition in male breast cancer patients: biological and clinical implications.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms, Male; Carcinoma; Estradiol; Humans; Letrozole; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Analysis; Testosterone; Treatment Outcome; Triazoles | 2010 |
Metastatic breast carcinoma presenting with profound hypocalcemia.
Topics: Adult; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Epilepsy, Tonic-Clonic; Female; Goserelin; Humans; Hypocalcemia; Neoplasm Metastasis | 2010 |
Efficacy of exemestane after nonsteroidal aromatase inhibitor use in metastatic breast cancer patients.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Metastasis; Retrospective Studies | 2012 |
Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?
Topics: Aged; Androstadienes; Antineoplastic Agents; Body Mass Index; Bone and Bones; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Interleukin-6; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tissue Distribution; Treatment Failure | 2003 |
Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Female; Humans; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Postmenopause; Receptors, Estrogen; Tamoxifen | 2004 |
Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma.
Topics: Adult; Aged; Androstadienes; Androstenedione; Aromatase; Aromatase Inhibitors; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Chondrosarcoma; Dose-Response Relationship, Drug; Estrogen Antagonists; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Receptors, Estrogen; RNA, Messenger; Signal Transduction | 2005 |
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2006 |
[Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Rate; Triazoles | 2008 |